• Describe the Progressive nature of CKD leading to significant morbidity and mortality
  • Discuss the disease burden of CKD and importance of screening and diagnosis
  • SGTL2i as recommended part of initial therapy in patients with T2D and CKD
  • Overview of DAPA-CKD trial and trial endpoints

This content is developed exclusively by or on behalf of the industry sponsor through a third party and is not reviewed by Pri-Med. The content and opinions expressed are those of the sponsor or presenters and may not reflect the views of Pri-Med.

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.